The Xpert MTB/RIF (Cepheid) test improved tuberculosis (TB) diagnosis and reduced time to treatment, but not long-term TB-related morbidity, according to the results of a multicenter, randomized, ...
The development of the Xpert MTB/RIF assay has been the most important breakthrough for the diagnosis of tuberculosis in decades. David L. Cohn This molecular-based test provides a rapid and sensitive ...
The overall failed test rate was 10.6% (range 5.9% in Moldova and Pakistan to 16.3% in the DRC). When data was pulled directly from the GeneXpert machine as opposed to the laboratory registers, a ...
Lung-Protective Ventilation Ups Outcomes Post-Abdominal Op Point-of-care Xpert MTB/RIF tuberculosis testing is associated with more patients getting same-day diagnosis and having same-day treatment ...
A study led by Frank Cobelens of the Amsterdam Institute of Global Health and Development, Amsterdam, The Netherlands and colleagues reports on the cost-effectiveness of implementing the Xpert MTB/RIF ...
Background: The identification of non-tuberculosis (TB) mycobacterial (NTM) infection remains a significant challenge. This study aims to investigate the diagnostic value of multicolour nested ...
Microbiological confirmation of childhood tuberculosis is rare because of the difficulty of collection of specimens, low sensitivity of smear microscopy, and poor access to culture. A new study aimed ...
The FDA has granted marketing approval for Xpert MTB/RIF Assay, the first FDA-reviewed test that can simultaneously detect bacteria that cause tuberculosis (TB) and determine if the bacteria contain ...
Tuberculosis (TB) causes more deaths globally than any other infectious disease and is a top 10 cause of death worldwide. Globally in 2017, of the estimated 10 million people with TB, 3.6 million were ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback